Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Prestige Consumer Healthcare (PBH) over the last 16 years, with Q4 2025 value amounting to -$495000.0.

  • Prestige Consumer Healthcare's Change in Receivables fell 10783.6% to -$495000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $27.3 million, marking a year-over-year increase of 38515.0%. This contributed to the annual value of $16.3 million for FY2025, which is 15825.69% up from last year.
  • Latest data reveals that Prestige Consumer Healthcare reported Change in Receivables of -$495000.0 as of Q4 2025, which was down 10783.6% from $29.9 million recorded in Q3 2025.
  • Prestige Consumer Healthcare's Change in Receivables' 5-year high stood at $29.9 million during Q3 2025, with a 5-year trough of -$27.3 million in Q2 2025.
  • Its 5-year average for Change in Receivables is $3.7 million, with a median of $2.0 million in 2022.
  • In the last 5 years, Prestige Consumer Healthcare's Change in Receivables crashed by 82497.95% in 2024 and then soared by 372604.32% in 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Change in Receivables (Quarter) stood at -$12.5 million in 2021, then skyrocketed by 170.56% to $8.8 million in 2022, then increased by 29.88% to $11.4 million in 2023, then crashed by 44.74% to $6.3 million in 2024, then plummeted by 107.84% to -$495000.0 in 2025.
  • Its last three reported values are -$495000.0 in Q4 2025, $29.9 million for Q3 2025, and -$27.3 million during Q2 2025.